Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis
NCT00748410 · GlaxoSmithKline · PHASE2 · terminated · last registry update 2020-10-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “SB-656933 is no longer being developed for ulcerative colitis.” | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-06-02Results posted on the registry: Dompé Farmaceutici S.p.A, paclitaxel + Reparixin (NCT02370238)
- 2021-05-14Also stopped (terminated): Dompé Farmaceutici S.p.A, Reparixin (NCT01861054)
- 2021-05-07Phase 3 first posted: Dompé Farmaceutici S.p.A, Reparixin (NCT04878055)
- 2021-04-19Results posted on the registry: Dompé Farmaceutici S.p.A, Paclitaxel+Reparixin (NCT02001974)
- 2021-03-29Also stopped (terminated): GlaxoSmithKline, Danirixin + Placebo (NCT03250689)
- 2021-03-25Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin (NCT01861054)
- 2021-03-12Phase 3 first posted: Dompé Farmaceutici S.p.A, Reparixin + Standard of care (NCT04794803)
- 2021-03-11Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin (NCT01220856)
- 2021-01-12Results posted on the registry: Dompé Farmaceutici S.p.A, Ladarixin + Placebo (NCT02814838)
- 2020-11-30Also stopped (terminated): GlaxoSmithKline, Danirixin 15 mg FBE + Danirixin 50 mg FBE (NCT02927431)
- 2020-07-31Also stopped (terminated): GlaxoSmithKline, Danirixin 35 mg tablets + Placebo (NCT03170232)
- 2020-04-14Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin continuous infusion + reparixin intermittent infusion (NCT00248040)
- 2020-02-05Results posted on the registry: GlaxoSmithKline, Danirixin 35 mg tablets + Placebo (NCT03170232)
- 2019-12-18Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin + Placebo (NCT01817959)
- 2019-11-29Results posted on the registry: GlaxoSmithKline, Danirixin + Danirixin matching placebo (NCT03034967)
- 2019-11-08Results posted on the registry: GlaxoSmithKline, Danirixin + Placebo (NCT03250689)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision